Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of LY2951742 for episodic cluster headache
NL-OMON45305Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cluster Headache (CH) comparing LY2951742 300 mg with Placebo (2 arms). Primary endpoint: Mean change in weekly cluster headache attack frequency from baseline to Week 3. Started Jan 2017; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON45305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45305.